PMID- 28849178 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20181113 IS - 1791-3004 (Electronic) IS - 1791-2997 (Print) IS - 1791-2997 (Linking) VI - 16 IP - 4 DP - 2017 Oct TI - Nerve growth factor pretreatment inhibits lidocaine‑induced myelin damage via increasing BDNF expression and inhibiting p38 mitogen activation in the rat spinal cord. PG - 4678-4684 LID - 10.3892/mmr.2017.7197 [doi] AB - The present study aimed to investigate the effect of exogenous nerve growth factor (NGF) pretreatment on demyelination in the spinal cord of lidocaine‑treated rats, and explored the potential neuroprotective mechanisms of NGF. A total of 36 rats were randomly assigned to three groups (n=12 per group): Sham group; Lido group, received intrathecal injection of lidocaine; NGF group, received intrathecal injection of NGF followed by intrathecal injection of lidocaine. Tail‑flick tests were used to evaluate neurobehavioral function. Ultrastructural alternations were analyzed by transmission electron microscopy. Immunofluorescence was used to examine the expression of myelin basic protein (MBP) and brain‑derived neurotrophic factor (BDNF). ELISA was used to determine serum levels of MBP and proteolipid protein (PLP). Western blotting was used to detect the expression of phosphorylated mitogen activated protein kinase (MAPK). NGF pretreatment reduced lidocaine‑induced neurobehavioral damage, nerve fiber demyelination, accompanied by a decrease in MBP expression in the spinal cord and an increase in MBP and PLP in serum. In addition, NGF pretreatment increased BDNF expression in the spinal cord of lidocaine‑treated rats. Furthermore, NGF pretreatment reduced p38 MAPK phosphorylation in the spinal cord of lidocaine‑treated rats. NGF treatment reduces lidocaine‑induced neurotoxicity via the upregulation of BDNF and inhibition of p38 MAPK. NGF therapy may improve the clinical use of lidocaine in intravertebral anesthesia. FAU - Zhao, Guangyi AU - Zhao G AD - Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China. FAU - Li, Dan AU - Li D AD - Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China. FAU - Ding, Xudong AU - Ding X AD - Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China. FAU - Li, Lu AU - Li L AD - Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China. LA - eng PT - Journal Article DEP - 20170809 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 9061-61-4 (Nerve Growth Factor) RN - 98PI200987 (Lidocaine) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) SB - IM MH - Animals MH - Brain-Derived Neurotrophic Factor/*genetics/metabolism MH - Gene Expression Regulation/*drug effects MH - Lidocaine/*pharmacology MH - Myelin Sheath/*drug effects/*metabolism/pathology MH - Nerve Growth Factor/*pharmacology MH - Phosphorylation MH - Rats MH - Signal Transduction/*drug effects MH - Spinal Cord/drug effects/metabolism/pathology MH - p38 Mitogen-Activated Protein Kinases/*metabolism PMC - PMC5647042 EDAT- 2017/08/30 06:00 MHDA- 2018/05/22 06:00 PMCR- 2017/08/09 CRDT- 2017/08/30 06:00 PHST- 2016/09/07 00:00 [received] PHST- 2017/05/19 00:00 [accepted] PHST- 2017/08/30 06:00 [pubmed] PHST- 2018/05/22 06:00 [medline] PHST- 2017/08/30 06:00 [entrez] PHST- 2017/08/09 00:00 [pmc-release] AID - mmr-16-04-4678 [pii] AID - 10.3892/mmr.2017.7197 [doi] PST - ppublish SO - Mol Med Rep. 2017 Oct;16(4):4678-4684. doi: 10.3892/mmr.2017.7197. Epub 2017 Aug 9.